Gene fusions between TMPRSS2 and ETS family genes in prostate cancer:: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues

被引:125
作者
Tu, Jiangling J.
Rohan, Stephen
Kao, Jean
Kitabayashi, Naoki
Mathew, Susan
Chen, Yao-Tseng
机构
[1] Weill Cornell Med Coll, Dept Pathol, New York, NY 10021 USA
[2] Weill Cornell Med Coll, Lab Med, New York, NY 10021 USA
关键词
TMPRSS2; ERG; translocation; microdeletion;
D O I
10.1038/modpathol.3800903
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Recurrent gene fusions between TMPRSS2 and ETS family genes have recently been shown to occur at a high frequency in prostate cancer. In this study, we used formalin-fixed paraffin-embedded tissue and evaluated both TMPRSS2-ERG and TMPRSS2-ETV1 fusions by reverse transcription polymerase chain reaction ( RT-PCR) and fluorescence in situ hybridization ( FISH). The results were correlated to overexpression of the downstream ERG and ETV1 sequences. Of 82 cases examined, TMPRSS2-ETV1 fusion was seen in only one case, by FISH. In comparison, TMPRSS2-ERG fusion was documented in 35 cases ( 43%) by either RT-PCR or FISH. Deletion, rather than translocation, was found to be the main mechanism for TMPRSS2-ERG gene fusion ( 81 vs 19%). RTPCR and FISH results correlated well, with most positive cases resulting in overexpression of downstream ERG sequences. Several TMPRSS2-ERG fusion transcript variants were identified, most of which are predicted to encode truncated ERG proteins. Prostate cancer of Gleason's scores 6 or 7 had more frequent TMPRSS2-ERG fusions than higher-grade tumors, but this difference was not statistically significant ( P= 0.42). On the other hand, mucin-positive carcinomas more often harbor such gene fusions when compared to mucin-negative tumors ( P = 0.004). These morphological correlates, and more importantly the potential correlation of such fusions to clinical outcome and treatment responses, should be further explored.
引用
收藏
页码:921 / 928
页数:8
相关论文
共 23 条
[1]   ETS-TMPRSS2 fusion gene products in prostate cancer [J].
Ahlers, Christoph M. ;
Figg, William D. .
CANCER BIOLOGY & THERAPY, 2006, 5 (03) :254-255
[2]   The role of genetic testing in soft tissue sarcoma [J].
Antonescu, CR .
HISTOPATHOLOGY, 2006, 48 (01) :13-21
[3]   Translocation carcinomas of the kidney [J].
Argani, P ;
Ladanyi, M .
CLINICS IN LABORATORY MEDICINE, 2005, 25 (02) :363-+
[4]   Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma [J].
Chen, YT ;
Tu, JLJ ;
Kao, J ;
Zhou, XK ;
Mazumdar, M .
CLINICAL CANCER RESEARCH, 2005, 11 (18) :6558-6566
[5]   Diversity of TMPRSS2-ERG fusion transcripts in the human prostate [J].
Clark, J. ;
Merson, S. ;
Jhavar, S. ;
Flohr, P. ;
Edwards, S. ;
Foster, C. S. ;
Eeles, R. ;
Martin, F. L. ;
Phillips, D. H. ;
Crundwell, M. ;
Christmas, T. ;
Thompson, A. ;
Fisher, C. ;
Kovacs, G. ;
Cooper, C. S. .
ONCOGENE, 2007, 26 (18) :2667-2673
[6]  
DEMICHELIS F, 2007, IN PRESS ONCOGENE
[7]   TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer [J].
Hermans, Karin G. ;
van Marion, Ronald ;
van Dekken, Herman ;
Jenster, Guido ;
van Weerden, Wytske M. ;
Trapman, Jan .
CANCER RESEARCH, 2006, 66 (22) :10658-10663
[8]   TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming [J].
Iljin, Kristiina ;
Wolf, Maija ;
Edgren, Henrik ;
Gupta, Santosh ;
Kilpinen, Sami ;
Skotheim, Rolf I. ;
Peltola, Mari ;
Smit, Frank ;
Verhaegh, Gerald ;
Schalken, Jack ;
Nees, Matthias ;
Kallioniemi, Olli .
CANCER RESEARCH, 2006, 66 (21) :10242-10246
[9]  
Jaffe ES., 2001, PATHOLOGY GENETICS T
[10]   THE EMERGING MOLECULAR-GENETICS OF SARCOMA TRANSLOCATIONS [J].
LADANYI, M .
DIAGNOSTIC MOLECULAR PATHOLOGY, 1995, 4 (03) :162-173